Table 1 Baseline characteristics of patients grouped by sarcopenia
From: Imaging-based diagnosis of sarcopenia for transplant-free survival in primary sclerosing cholangitis
Parameters | All Patients | Sarcopenia | No-sarcopenia | p-value |
|---|---|---|---|---|
(N) = available cases if values are missing | % (total number) or median/mean (range/SD) | |||
Number of patients | 95 | 62.1% (59) | 37.9% (36) | – |
Sex | Â | Â | Â | 0.310 |
 Male | 67.4% (64) | 71.2% (42) | 61.1% (22) |  |
 Female | 32.6% (31) | 28.8% (17) | 38.9% (14) |  |
Age (median, range, in years) | 45 (18–76) | 46 (18–76) | 41 (23–64) | 0.369 |
BMI | 25.7 (7.7) | 24.8 (8.1) | 27.1 (6.9) | 0.167 |
PSC-IBD | 70.5% (67) | 66.1% (39) | 77.8% (28) | 0.226 |
Liver cirrhosis | 51.6% (48) | 61.0% (36) | 33.3% (12) | 0.017 |
LTX | 35.8% (34) | 47.5% (28) | 16.7% (6) | 0.002 |
Death | 11.6% (11) | 18.6% (11) | 0% (0) | 0.006 |
LTX/death (primary endpoint) | 47.4% (45) | 66.1% (39) | 16.7% (6) | < 0.001 |
Malignancy | 20.0% (19) | 25.4% (15) | 11.1% (4) | 0.091 |
Dominant stenosis | 67.4% (64) | 69.5% (41) | 61.9% (23) | 0.572 |
Ascites | 40.0% (38) | 54.2% (32) | 16.7% (6) | < 0.001 |
Hepatic Encephalopathy | 13.7% (13) | 16.9% (10) | 8.3% (3) | 0.236 |
Splenomegaly | 48.4% (46) | 57.6% (34) | 33.3% (12) | 0.022 |
BMI reduction > 10% in 12 months | 16.8% (16) | 22.0% (13) | 8.3% (3) | 0.083 |
Recurring cholangitis (≥ 2x/6 months) | 16.8% (16) | 22.0% (13) | 8.3% (3) | 0.083 |
SEG | 27.4% (26) | 37.3% (22) | 11.1% (4) | 0.006 |
MELD score (n = 94) | 13.1 (8.2) | 14.9 (8.7) | 9.9 (6.2) | 0.002 |
Child-Pugh Grade (n = 48) |  |  |  | 0.001 |
 A | 25.0% (12) | 13.9% (5) | 58.3% (7) |  |
 B | 50.0% (24) | 55.6% (20) | 33.3% (4) |  |
 C | 25.0% (12) | 30.6% (11) | 08.3% (1) |  |
Mayo risk score (n = 67) | 1.70 (1.87) | 2.27 (1.81) | 0.62 (1.52) | <0.001 |
EASL 2022 CPG risk stratification |  |  |  | < 0.001 |
 Low risk | 22.1% (21) | 15.3% (9) | 33.3% (12) |  |
 Significant risk | 77.9% (74) | 84.7% (50) | 66.7% (24) |  |
Platelets (103cells/µl) | 227 (149) | 231 (169) | 219 (110) | 0.708 |
Albumin (g/dl) (n = 67) | 3.64 (0.86) | 3.36 (0.86) | 4.19 (0.57) | < 0.001 |
Bilirubin (mg/dl) | 5.0 (7.7) | 6.5 (8.8) | 2.7 (4.7) | 0.019 |
INR (n = 90) | 1.21 (0.41) | 1.29 (0.45) | 1.07 (0.32) | 0.012 |
Creatinine (mg/dl) | 0.9 (0.5) | 0.9 (0.5) | 0.9 (0.6) | 0.855 |
Sodium (mmol/l) (n = 90) | 138 (4) | 137 (5) | 140 (2) | < 0.001 |
Mode of cross-sectional imaging | Â | Â | Â | 0.070 |
 CT | 58.9% (56) | 66.1% (39) | 47.2% (17) |  |
 MRI | 41.1% (39) | 33.9% (20) | 52.8% (19) |  |
Time interval between diagnosis of PSC and date of last imaging (years) | 8.89 (7.52) | 8.95 (7.71) | 8.81 (7.32) | 0.929 |
Loss to follow-up | 23.2% (22) | 15.3% (9) | 36.1% (13) | 0.019 |
Time of follow-up (years) | 1.35 (2.06) | 1.06 (1.66) | 1.82 (2.53) | 0.078 |
SMI (cm²/m²) | 42.08(9.35) | 37.55 (7.63) | 49.49 (6.31) | < 0.001 |